![]() | This article is rated Stub-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
Inhibitors of gamma and delta isoforms of PI3K in particular. Rod57 ( talk) 19:22, 9 July 2010 (UTC)
Especially any phase III or even II. Rod57 ( talk) 12:32, 25 August 2010 (UTC)
Rod57 ( talk) 10:58, 20 October 2010 (UTC)
[1]
says "PI-103 is a potent, ATP-competitive PI3K inhibitor of DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ with IC50 of 2 nM, 8 nM, 20 nM, 26 nM, 48 nM, 83 nM, 88 nM and 150 nM, respectively." and implies there have been some clinical trials.
[2] says some derivatives of PI-103 such as
GDC-0941 have been in clinical trials. Also "GDC-0941 is a potent inhibitor of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ with IC50 of 3 nM, 33 nM, 3 nM and 75 nM, respectively". -
Rod57 (
talk)
00:10, 24 October 2012 (UTC)
Hello fellow Wikipedians,
I have just added archive links to one external link on Phosphoinositide 3-kinase inhibitor. ... I made the following changes:
An editor has reviewed this edit and fixed any errors that were found.
Cheers.— cyberbot II Talk to my owner:Online 21:23, 29 January 2016 (UTC)
Should clarify if all are inhibitors of only class I PI3K - perhaps a section saying what is known about class II, III or IV PI3K inhibitors ? - Rod57 ( talk) 13:20, 30 January 2017 (UTC)
Hello fellow Wikipedians,
I have just modified 2 external links on Phosphoinositide 3-kinase inhibitor. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
{{
dead link}}
tag to
http://www.tradingmarkets.com/news/stock-alert/onty_oncothyreon-presents-phase-1-data-for-px-866-and-px-478-at-asco-annual-meeting-973189.html{{
dead link}}
tag to
http://rhizen.com/News%20%26%20PR/Rhizen_Press%20Release_ATS_May%2713.pdfWhen you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018.
After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than
regular verification using the archive tool instructions below. Editors
have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the
RfC before doing mass systematic removals. This message is updated dynamically through the template {{
source check}}
(last update: 5 June 2024).
Cheers.— InternetArchiveBot ( Report bug) 01:12, 31 March 2017 (UTC)
Hello fellow Wikipedians,
I have just modified one external link on Phosphoinositide 3-kinase inhibitor. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018.
After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than
regular verification using the archive tool instructions below. Editors
have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the
RfC before doing mass systematic removals. This message is updated dynamically through the template {{
source check}}
(last update: 5 June 2024).
Cheers.— InternetArchiveBot ( Report bug) 07:01, 1 April 2017 (UTC)
The only drug mentioned as both 'notable example' as well as in "approvals" is Duvelisib. The other approved drugs are not referred to as noteworthy examples. It is also noteworthy that only for duvelisib the tradename is mentioned in the paragraph.
I don't find duvelisib to be an especially noteworthy drug, compared to the other two approved drugs. I also do think stuff like tradename should be part of the respective article for the substance (like it is fine for the other two approved drugs).
Please be aware I do have a COI and thus will not edit the article myself.
Wowbagger2 ( talk) 10:09, 7 January 2019 (UTC)
![]() | This article is rated Stub-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
Inhibitors of gamma and delta isoforms of PI3K in particular. Rod57 ( talk) 19:22, 9 July 2010 (UTC)
Especially any phase III or even II. Rod57 ( talk) 12:32, 25 August 2010 (UTC)
Rod57 ( talk) 10:58, 20 October 2010 (UTC)
[1]
says "PI-103 is a potent, ATP-competitive PI3K inhibitor of DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ with IC50 of 2 nM, 8 nM, 20 nM, 26 nM, 48 nM, 83 nM, 88 nM and 150 nM, respectively." and implies there have been some clinical trials.
[2] says some derivatives of PI-103 such as
GDC-0941 have been in clinical trials. Also "GDC-0941 is a potent inhibitor of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ with IC50 of 3 nM, 33 nM, 3 nM and 75 nM, respectively". -
Rod57 (
talk)
00:10, 24 October 2012 (UTC)
Hello fellow Wikipedians,
I have just added archive links to one external link on Phosphoinositide 3-kinase inhibitor. ... I made the following changes:
An editor has reviewed this edit and fixed any errors that were found.
Cheers.— cyberbot II Talk to my owner:Online 21:23, 29 January 2016 (UTC)
Should clarify if all are inhibitors of only class I PI3K - perhaps a section saying what is known about class II, III or IV PI3K inhibitors ? - Rod57 ( talk) 13:20, 30 January 2017 (UTC)
Hello fellow Wikipedians,
I have just modified 2 external links on Phosphoinositide 3-kinase inhibitor. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
{{
dead link}}
tag to
http://www.tradingmarkets.com/news/stock-alert/onty_oncothyreon-presents-phase-1-data-for-px-866-and-px-478-at-asco-annual-meeting-973189.html{{
dead link}}
tag to
http://rhizen.com/News%20%26%20PR/Rhizen_Press%20Release_ATS_May%2713.pdfWhen you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018.
After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than
regular verification using the archive tool instructions below. Editors
have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the
RfC before doing mass systematic removals. This message is updated dynamically through the template {{
source check}}
(last update: 5 June 2024).
Cheers.— InternetArchiveBot ( Report bug) 01:12, 31 March 2017 (UTC)
Hello fellow Wikipedians,
I have just modified one external link on Phosphoinositide 3-kinase inhibitor. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018.
After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than
regular verification using the archive tool instructions below. Editors
have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the
RfC before doing mass systematic removals. This message is updated dynamically through the template {{
source check}}
(last update: 5 June 2024).
Cheers.— InternetArchiveBot ( Report bug) 07:01, 1 April 2017 (UTC)
The only drug mentioned as both 'notable example' as well as in "approvals" is Duvelisib. The other approved drugs are not referred to as noteworthy examples. It is also noteworthy that only for duvelisib the tradename is mentioned in the paragraph.
I don't find duvelisib to be an especially noteworthy drug, compared to the other two approved drugs. I also do think stuff like tradename should be part of the respective article for the substance (like it is fine for the other two approved drugs).
Please be aware I do have a COI and thus will not edit the article myself.
Wowbagger2 ( talk) 10:09, 7 January 2019 (UTC)